All IHC stains will include a positive control tissue on each slide.
FFPE tissue block
AHL – Immunohistochemistry
Days Set Up:
Mo - Fr
1 - 2 days
If requested, an interpretive report will be provided
Collection/ Processing Details:
This antibody is used to identify the androgen receptor in tumor cells.
Strong nuclear staining
Androgen receptor (AR) positivity may be used to identify patients with metastatic breast cancer who may benefit from Bicalutamide therapy (prostate cancer drug).
The majority of estrogen receptor positive breast cancers will also be AR positive; androgen receptors are most frequently seen in luminal A and B invasive breast cancers.
ARs are also seen in approximately one-third of basal-like cancers
AR positive, estrogen receptor negative tumors are frequently apocrine type; these may be triple negative or HER2 positive tumors.
Request AR IHC evaluation on breast cases using image analysis.
AR is also useful in the diagnosis of salivary duct carcinomas. Approximately 90% of these tumors will be AR positive, and P63 negative.
1. Niemeier LA, Dabbs DJ et al: Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol (2010) 23, 205–212.
2. Collins LC et al: Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study. Mod Pathol. 2011 July; 24(7): 924–931. doi:10.1038/modpathol.2011.54
3. Robinson JLL et al: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. The EMBO Journal (2011) 30, 3019–3027.